Nomenclature
Short Name:
PYK2
Full Name:
Protein tyrosine kinase 2 beta
Alias:
- CADTK
- EC 2.7.10.2
- FADK 2
- FADK2, FAK2
- FAK2
- Related adhesion focal tyrosine kinase; RAFTK
- CAK beta
- CAKB
- Calcium-dependent tyrosine kinase
- Cell adhesion kinase beta
Classification
Type:
Protein-tyrosine kinase
Group:
TK
Family:
Fak
SubFamily:
NA
Specific Links
Structure
Mol. Mass (Da):
115,875
# Amino Acids:
1009
# mRNA Isoforms:
2
mRNA Isoforms:
115,875 Da (1009 AA; Q14289); 111,183 Da (967 AA; Q14289-2)
4D Structure:
Interacts with Crk-associated substrate (Cas), PTPNS1 and SH2D3C By similarity. Interacts with nephrocystin, ASAP2, OPHN1L, SKAP2 and TGFB1I1.
1D Structure:
3D Image (rendered using PV Viewer):
PDB ID
Subfamily Alignment
Domain Distribution:
Kinexus Products
Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K564.
Serine phosphorylated:
S2, S9, S332, S361, S375, S394, S396, S399, S473, S530, S559, S571, S583+, S718, S746, S747, S752, S758, S762, S778, S828, S839, S866, S923.
Threonine phosphorylated:
T15, T409, T701, T749, T765, T842, T853.
Tyrosine phosphorylated:
Y402+, Y418, Y440, Y573+, Y579+, Y580+, Y683, Y699, Y722, Y756, Y819, Y834, Y849, Y881, Y906+.
Ubiquitinated:
K188, K206, K564, K858, K911, K944, K973.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
- 81
1048
32
1886
- 3
34
16
27
- 15
189
32
427
- 40
525
119
910
- 47
607
24
524
- 2
28
74
28
- 31
400
35
640
- 26
341
60
542
- 29
378
17
316
- 12
160
114
247
- 10
125
53
278
- 44
575
216
592
- 23
293
54
321
- 3
33
15
29
- 7
87
19
69
- 3
34
16
24
- 6
84
225
159
- 12
155
43
257
- 3
34
113
72
- 34
436
109
467
- 11
149
47
280
- 16
208
51
213
- 15
198
42
338
- 14
178
43
514
- 26
335
47
402
- 33
424
76
569
- 13
167
57
182
- 13
171
43
316
- 9
122
43
237
- 43
558
28
452
- 52
677
36
490
- 100
1300
36
2635
- 6
81
72
121
- 61
795
57
703
- 3
36
44
38
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
- 100
100
100 - 99.6
99.8
99.5 - 98.8
99.6
99 - -
-
95 - -
-
95 - 96.2
98.8
96 - -
-
- - 95.5
98.1
95 - 95.6
98.1
94 - -
-
- - 63.1
70.1
- - 44.8
62.2
80 - 43.8
61.8
77 - 59.4
75.1
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
- - -
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
No. | Name – UniProt ID |
---|---|
1 | BCAR1 - P56945 |
2 | PTPN12 - Q05209 |
3 | PTPN6 - P29350 |
4 | CBL - P22681 |
5 | EGFR - P00533 |
6 | EFS - O43281 |
7 | DCC - P43146 |
8 | SH2D3C - Q8N5H7 |
9 | RB1CC1 - Q8TDY2 |
10 | KCNA2 - P16389 |
11 | IL7R - P16871 |
12 | ITGB3 - P05106 |
13 | FLT1 - P17948 |
14 | STAT3 - P40763 |
15 | ERBB3 - P21860 |
Regulation
Activation:
Phosphorylation at Tyr-402 increases phosphotransferase activity and induces interaction with ErbB2, RasGAP and Src. Phosphorylation at Tyr-579 increases phosphotransferase activity.
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Known Upstream Kinases
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
Kinase Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
---|
Known Downstream Substrates
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
Substrate Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
---|
ARA55 (Hic-5) | O43294 | Y60 | SGDKDHLYSTVCKPR | - |
DDEF1 | Q9ULH1 | Y767 | RDKQRLSYGAFTNQI | |
eNOS | P29474 | Y657 | FGLGSRAYPHFCAFA | |
FAK (PTK2) | Q05397 | Y407 | IIDEEDTYTMPSTRD | + |
Hic-5 | O43294 | Y60 | SGDKDHLYSTVCKPR | - |
JAK2 | O60674 | Y1007 | VLPQDKEYYKVKEPG | + |
JAK2 | O60674 | Y1008 | LPQDKEYYKVKEPGE | + |
PXN | P49023 | Y118 | VGEEEHVYSFPNKQK | |
PXN | P49023 | Y31 | FLSEETPYSYPTGNH | |
PYK2 (PTK2B) | Q14289 | Y402 | CSIESDIYAEIPDET | + |
SNCA | P37840 | Y125 | VDPDNEAYEMPSEEG | |
Src | P12931 | Y419 | RLIEDNEYTARQGAK | + |
TGFb1I1 | O43294 | Y60 | SGDKDHLYSTVCKPR | - |
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Experimentally derived from alignment of 22 known protein substrate phosphosites and 43 peptides phosphorylated by recombinant PYK2 in vitro tested in-house by Kinexus.
Domain #:
1
Inhibitors
For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
Compound Name | KD, Ki or IC50 (nM) | PubChem ID | ChEMBL ID | PubMed ID |
---|
Disease Linkage
General Disease Association:
Cancer
Specific Cancer Types:
Gliomas; Hepatocellular carcinomas; Lung cancer (LC); Breast cancer
Gene Expression in Cancers:
The COSMIC website notes an up-regulated expression score for PYK2 in diverse human cancers of 278, which is 0.6-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 55 for this protein kinase in human cancers was 0.9-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis. PYK2 autophosphorylation and interaction with Src can be inhibited with an Y402F mutation. Its phosphotransferase activity can be abrogated with a K457A mutation. NPHP1 interaction with PYK2 can be interrupted with a P859A mutation. A Y881F mutation can impair interaction with the GRB2 adapter protein.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.08 % in 25546 diverse cancer specimens. This rate is very similar (+ 10% higher) to the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.57 % in 944 skin cancers tested; 0.35 % in 589 stomach cancers tested; 0.27 % in 1270 large intestine cancers tested; 0.21 % in 603 endometrium cancers tested; 0.17 % in 238 bone cancers tested; 0.15 % in 1634 lung cancers tested; 0.08 % in 891 ovary cancers tested; 0.06 % in 710 oesophagus cancers tested; 0.06 % in 1512 liver cancers tested; 0.06 % in 1490 breast cancers tested; 0.05 % in 548 urinary tract cancers tested; 0.04 % in 558 thyroid cancers tested; 0.04 % in 273 cervix cancers tested; 0.04 % in 2082 central nervous system cancers tested.
Frequency of Mutated Sites:
Most frequent mutations with the number of reports indicated in brackets: R671C (3).
Comments:
Only 6 deletions, no insertions or complex mutations are noted on the COSMIC website.